94 results about "Reperfusion Damages" patented technology

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.

The invention belongs to the field of traditional Chinese medicine chemistry and natural product separation, and particularly relates to extraction and separation of a novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol and application of the novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol in myocardial protection drugs. The compound is named as 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol, and the structural formula of the compound is shown in the description. The invention provides an extraction and separation method of the compound. The extraction and separation method mainly comprises the following steps: sequentially carrying out solvent extraction, macroporous adsorption resin enrichment, silica gel column chromatography, ODS medium-pressure column chromatography, high performance liquid chromatography separation and purification and the like on ginseng and other traditional Chinese medicine processed products and hydrolysates. The structure of the compound is determined through comprehensive analysis of a high-resolution mass spectrum (HRMS), one-dimensional nuclear magnetic resonance (1H NMR, 13C NMR) and a two-dimensional nuclear magnetic resonance spectrum (such as HSQC, HMBC, ROESY and the like), and the compound is a newly discovered dammarane type triterpene compound. Experiments show that the compound and the composition thereof have a remarkable protection effect on myocardial cell hypoxia / reoxygenation reperfusion injury, and can be used for preparing drugs for preventing or treating myocardial ischemia reperfusion injury and other related diseases.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

A device comprising interconnected components for deoxygenating blood used in the treatment and prevention of reperfusion injury, including a configuration to reduce the ionized calcium concentration of the deoxygenated blood to less than 0.5 mmol / L. The components may include a syringe pump operably communicating with various configurations via a control unit / processor, a cannula, a pump communicating with the cannula, a heat exchanger, a device for generating / creating fluid flow, an infusion port, a mixing port, a device hub, and a catheter hub. These components are selectively connected to a subject, and monitoring and / or other lead wires / devices may be attached to the subject. The lead wires / devices may include sensors and other devices that can be attached to / connected to the subject, providing health indicators, such as a temperature sensor, electrodes for monitoring cardiac electrical activity, and an oxygen saturation (SpO2) sensor for monitoring the patient's blood oxygen saturation.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The application relates to a dual-purpose maintenance system for taking out a heart and maintaining the heart extracorporeally, which comprises a perfusion pipeline assembly and an organ box. The design that the organ box is communicated with a blood storage container and is switched can support the no-stop-taking-out and transportation operation of the heart. In the conversion process, the pipeline does not need to be replaced, the heat ischemic injury and ischemia-reperfusion injury of the heart are reduced.

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

This invention discloses a micropeptide, its encoding nucleic acid, and its application in regulating inflammatory activation of microglia. The amino acid sequence of the micropeptide is shown in SEQ ID NO:3. Simultaneously, this invention discloses the nucleic acid encoding the micropeptide, which contains either the nucleotide sequence shown in SEQ ID NO:1 or the nucleotide sequence shown in SEQ ID NO:2, wherein SEQ ID NO:2 is a small open reading frame located within the sequence of SEQ ID NO:1. This invention validated the translational expression of the micropeptide in microglia by constructing an EGFP reporter gene fusion vector and a SUMO tag fusion expression vector. Functional experiments showed that under oxygen-glucose deprivation / reperfusion injury conditions, the micropeptide significantly inhibited inflammatory activation of microglia. This invention provides a new potential target and candidate drug for the treatment of neuroinflammatory diseases such as stroke.

Compounds, compositions and methods for improving the viability and / or function of cells or for the in vitro, ex vivo or in vivo protection of cells, tissue, graft or organs from various damages are described. The reagents and composition are based on activation of the heat shock response activation and / or the antioxidant response and include for example. HSP90 co-factor inhibitor such as Celastrol or Celastrol analogs used alone or in combination with an adjunct agent (e.g., a NRF-2 activator, antioxidant, etc.). Therapeutic enhancement may also include increase in paracrine effector production and signaling. Methods for improving the resistance of cells, tissue, grafts or organs to damages or stress, such as hypoxic or oxidative stress-induced cell death, and / or for improving the viability and retention of transplanted or transfused cells are also described. Therapeutic treatment or prevention of ischemic injury (e.g. myocardial infarct, ischemia / reperfusion injury) and related stressors (hypoxia, oxidative stress, inflammation, sepsis / shock, etc) are also provided.

Provided is a pharmaceutical composition and application thereof, specifically, said pharmaceutical composition comprises: salvianolic acid B as a first active ingredient; and ginsenoside Rg1 as a second active ingredient, and the weight ratio of the first active ingredient to the second active ingredient being 5:(1-4.5). The pharmaceutical composition has a better active-ingredient proportion than the prior art, has a better therapeutic efficacy in preventing and / or treating ischemic diseases, and ischemia-reperfusion tissue or organ damage, and can be used for treating ischemia and / or ischemia-reperfusion damage of different tissues and organs.

The invention relates to the field of pharmaceutical compositions for promoting atherosclerosis, in particular to a lipid oxide-AGEs composite pharmaceutical composition for promoting atherosclerosis, a method for constructing a rat coronary heart disease ischemia reperfusion injury model by using the composition and application of the composition. The composition comprises 80-90 parts of oxidized lipid, 4-6 parts of 7-ketocholesterol, 2-4 parts of 25-hydroxycholesterol, 8-10 parts of trans-fatty acid, 200-300 parts of an advanced glycosylation end product, 180-220 parts of casein, 320-360 parts of cane sugar, 145-165 parts of corn starch, 45-55 parts of cellulose, 30-40 parts of a mineral mixture, 8-12 parts of a vitamin mixture and 0.4-0.6 mg / kg of folic acid, the vitamin B6 is 1.8 to 2.2 mg / kg, and the vitamin B12 is 0.007 to 0.009 mg / kg.

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

Compounds, compositions and methods for improving the viability and / or function of cells or for the in vitro, ex vivo or in vivo protection of cells, tissue, graft or organs from various damages are described. The reagents and composition are based on activation of the heat shock response and / or the antioxidant response and include for example, HSP90 co-factor inhibitor such as Celastrol or Celastrol analogs used alone or in combination with an adjunct agent (e.g., a NRF-2 activator, antioxidant, etc.). Therapeutic enhancement may also include increase in paracrine effector production and signaling. Methods for improving the resistance of cells, tissue, grafts or organs to damages or stress, such as hypoxic or oxidative stress-induced cell death, and / or for improving the viability and retention of transplanted or transfused cells are also described. Therapeutic treatment or prevention of ischemic injury (e.g. myocardial infarct, ischemia / reperfusion injury) and related stressors (hypoxia, oxidative stress, inflammation, sepsis / shock, etc) are also provided.

The invention discloses an application of biotin in preparation of a medicine for treating or preventing ischemia-reperfusion injury, the biotin is applied to intervention research of ischemia-reperfusion injury for the first time, and the protective effect of the biotin in a cell inflammation model and an animal ischemia-reperfusion model is systematically verified. A solid experimental foundation is laid for application of the method in treatment of related diseases such as lung ischemia reperfusion injury and ischemia reperfusion induced pulmonary arterial hypertension, and a brand-new intervention strategy is provided.

The present disclosure relates to an annexin A1 (AnxA1) N-terminal peptide and a pharmaceutical composition comprising such an annexin A1 (AnxA1) N-terminal peptide for use in the treatment of ischemic disorders and / or reperfusion injury.

The invention relates to the technical field of biological medicine, in particular to an efficient macrophage targeting vesicle system as well as a preparation method and application thereof. The vesicle system is a chimeric vesicle (mHEs), and is prepared from extracellular vesicles (M2-EVs) derived from M2 type macrophages and apoptotic small bodies (MSC-ABs) derived from bone marrow mesenchymal stem cells. The vesicle system provided by the invention can realize specific recognition and functional regulation of macrophages, thereby playing an efficient therapeutic role in pathological processes such as tissue inflammation repair, myocardial infarction, ischemia-reperfusion injury and immune metabolism remodeling.

The invention belongs to the technical field of nursing vests, and discloses a multi-mode vital sign intelligent nursing vest which comprises a front vest, and a patch opening is formed in the front face of the front vest. By arranging the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, due to the design of the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, respiration, electrocardio, body temperature and muscular tension of a patient can be monitored in real time, and monitored data are transmitted to the single chip microcomputer; the single-chip microcomputer monitors vital signs and neurological function changes of a patient in real time through an AI algorithm, automatically warns the risk of encephaledema, epileptic seizure or reperfusion injury, and transmits the monitored vital signs and neurological function changes of the patient to the medical system through the data transmission module. Meanwhile, when it is monitored that the vital signs and the neurological functions of the patient are abnormal, an alarm is given out through the alarm to remind medical staff.

The application relates to a method for constructing a myocardial ischemia-reperfusion injury model, inserting a blood vessel blocking body into a blood vessel of a target mouse and sending the blood vessel blocking body to a position of a coronary artery to be blocked, blocking the position of the coronary artery to be blocked by using the blood vessel blocking body, and making part or all of the blood vessel blocking body made of biodegradable material, so as to simulate myocardial ischemia-reperfusion injury through degradation of the blood vessel blocking body in the target mouse. The blood vessel blocking body is made of biodegradable material, the biodegradable material can be degraded in the animal body, myocardial ischemia-reperfusion can be simulated without additional operation, the different thicknesses of the degradable parts of the blood vessel blocking body can be set, the coronary artery ischemia-reperfusion time can be accurately controlled, the controllability of the reperfusion time is improved, and the disease process and reperfusion injury of human myocardial ischemia / acute myocardial infarction can be accurately simulated.

The application discloses a kind of nano preparation for treating ischemia-reperfusion injury and its preparation method and application, belong to the field of pharmaceutical preparation, the nano preparation includes active ingredient, albumin, liposome phospholipid bilayer and target head, active ingredient is composed of antioxidant and coenzyme Q10 and its analog, liposome phospholipid bilayer is composed of phospholipid, cholesterol and DSPE-mPEG 2000 Composition, the nano preparation can both remove active oxygen produced in cell and relieve intracellular oxidative stress, also can enter mitochondrial inner membrane and help mitochondrial respiratory chain electron transfer, repair damaged mitochondrial function, reduce the generation of active oxygen from root, so as to play the effect of treating both symptoms and root cause.The application proposes a kind of new strategy for treating ischemia-reperfusion injury related diseases, by removing active oxygen, effectively restoring blocked electron transport chain, improving the antioxidant capacity of cell itself, reducing oxidative damage caused by ferroptosis, with good practical application prospect.

The application discloses an application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicines.The application provides an application of the RNF130 activator in preparation of a medicine for preventing or treating kidney ischemia-reperfusion injury, and the RNF130 activator can improve kidney function of a mouse with kidney ischemia-reperfusion injury, improve levels of blood creatinine, urea nitrogen and cystatin C, reduce levels of kidney injury markers KIM-1 and LCN2, and reduce tubular injury, thereby playing a preventive and therapeutic role on kidney ischemia-reperfusion injury, and providing a new target for preparation of a medicine for preventing and treating acute kidney injury.

The invention discloses a screening method of anti-cerebral ischemic injury active components of a salvia miltiorrhiza-cortex moutan medicine, a targeted brain-entering composition and application thereof, and belongs to the technical field of traditional Chinese medicines. The pharmaceutical composition for resisting cerebral ischemic injury is prepared by compatibility of radix salviae miltiorrhizae and cortex moutan, blood-entering active components of the pharmaceutical composition comprise various components such as gallic acid, and paeoniflorin and the like are targeted brain-entering components. The invention also provides a method for screening the active ingredients of the composition in blood, which comprises the following steps: preparing a test sample and a mixed reference substance solution, and analyzing and determining the ingredients by high performance liquid chromatography and high resolution mass spectrometry. The composition can be used for preparing drugs for resisting cerebral ischemia injury, can improve the neurological function of rats and the like, and is suitable for treating acute and chronic cerebral ischemia and reperfusion injury. In addition, the active ingredients entering blood can be used for preparing drugs for promoting angiogenesis of cerebral vessels, and the BMECs related capacity of OGD / R damaged rats is improved. The invention provides a new direction and choice for treatment of cerebral ischemia injury.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

Disclosed are acid-sensing ion channel (ASIC) inhibitors and their use for treating or inhibiting the development of a condition in which inhibiting an ASIC stimulates or effects treatment or inhibition of the development of the condition. More particularly, this invention relates to proteinaceous ASIC inhibitors and their use for treating or inhibiting the development of a neurological condition, neuronal damage, ischaemia, pain, ischaemia-reperfusion injury, a cancer, chronic kidney disease, acute kidney injury, arthritis and retinal detachment. The ASIC inhibitors are also useful for inhibiting damage to an organ during organ transplantation.

The invention discloses an application of picrogenin A in preparation of a medicine for treating ischemia-reperfusion injury. The invention proposes and verifies that the kuichnogenin A can inhibit ferroptosis to prevent and treat cerebral ischemia reperfusion injury for the first time, including greatly reducing the volume of cerebral infarction caused by cerebral ischemia reperfusion; the invention provides a plant-derived natural medicine for treating cerebral ischemia reperfusion injury, which has great application potential, and can be used for remarkably improving neurological function injury symptoms such as autonomous activity reduction, sensory motor function damage and motor coordination reduction caused by cerebral ischemia reperfusion, and the invention provides a plant-derived natural medicine for treating cerebral ischemia reperfusion injury.

The invention relates to an application of a composition in preparation of a medicine for preventing, relieving and / or treating myocardial ischemia / reperfusion injury, the composition contains telaprevir and tidutinib, and the mass ratio of the telaprevir to the tidutinib is (100: 1)-(1: 100). The medicine disclosed by the invention has a good effect on treating myocardial ischemia / reperfusion injury (including myocardial infarction), and telaprevir and sidumatinib show a synergistic effect, so that an excellent curative effect is favorably obtained, the dosage of the medicine is reduced, and the clinical medication safety is favorably improved.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.